Cargando…

Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study

BACKGROUND: A goal of malaria epidemiological interventions is the detection and treatment of parasite reservoirs in endemic areas—an activity that is expected to reduce local transmission. Since the gametocyte is the only transmissible stage from human host to mosquito vector, this study evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosasih, Ayleen, Koepfli, Cristian, Dahlan, M. Sopiyudin, Hawley, William A., Baird, J. Kevin, Mueller, Ivo, Lobo, Neil F., Sutanto, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034167/
https://www.ncbi.nlm.nih.gov/pubmed/33836772
http://dx.doi.org/10.1186/s12936-021-03709-y
_version_ 1783676495970959360
author Kosasih, Ayleen
Koepfli, Cristian
Dahlan, M. Sopiyudin
Hawley, William A.
Baird, J. Kevin
Mueller, Ivo
Lobo, Neil F.
Sutanto, Inge
author_facet Kosasih, Ayleen
Koepfli, Cristian
Dahlan, M. Sopiyudin
Hawley, William A.
Baird, J. Kevin
Mueller, Ivo
Lobo, Neil F.
Sutanto, Inge
author_sort Kosasih, Ayleen
collection PubMed
description BACKGROUND: A goal of malaria epidemiological interventions is the detection and treatment of parasite reservoirs in endemic areas—an activity that is expected to reduce local transmission. Since the gametocyte is the only transmissible stage from human host to mosquito vector, this study evaluated the pre and post presence of gametocytes during a mass screening and treatment (MST) intervention conducted during 2013 in East Nusa Tenggara, Indonesia. METHODS: RT-qPCR targeting pfs25 and pvs25 transcripts—gametocyte molecular markers for Plasmodium falciparum and Plasmodium vivax, respectively, was performed to detect and quantify gametocytes in blood samples of P. falciparum and P. vivax-infected subjects over the course of the MST study. The presence of both asexual and sexual parasites in microscopic and submicroscopic infections was compared from the start and end of the MST, using proportion tests as well as parametric and non-parametric tests. RESULTS: Parasite prevalence remained unchanged for P. falciparum (6% = 52/811 versus 7% = 50/740, p = 0.838), and decreased slightly for P. vivax (24% = 192/811 versus 19% = 142/740, p = 0.035) between the MST baseline and endpoint. No significant difference was observed in gametocyte prevalence for either P. falciparum (2% = 19/803 versus 3% = 23/729, p = 0.353, OR = 1.34, 95%CI = 0.69–2.63), or P. vivax (7% = 49/744 versus 5% = 39/704, p = 0.442, OR = 0.83, 95%CI = 0.52–1.31). Even though there was an insignificant difference between the two time points, the majority of parasite positive subjects at the endpoint had been negative at baseline (P. falciparum: 66% = 29/44, P. vivax: 60% = 80/134). This was similarly demonstrated for the transmissible stage—where the majority of gametocyte positive subjects at the endpoint were negative at baseline (P. falciparum: 95% = 20/21, P. vivax: 94% = 30/32). These results were independent of treatment provided during MST activities. No difference was demonstrated in parasite and gametocyte density between both time points either in P. falciparum or P. vivax. CONCLUSION: In this study area, similar prevalence rates of P. falciparum and P. vivax parasites and gametocytes before and after MST, although in different individuals, points to a negligible impact on the parasite reservoir. Treatment administration based on parasite positivity as implemented in the MST should be reevaluated for the elimination strategy in the community. Trial registration Clinical trials registration NCT01878357. Registered 14 June 2013, https://www.clinicaltrials.gov/ct2/show/NCT01878357. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-021-03709-y.
format Online
Article
Text
id pubmed-8034167
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80341672021-04-12 Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study Kosasih, Ayleen Koepfli, Cristian Dahlan, M. Sopiyudin Hawley, William A. Baird, J. Kevin Mueller, Ivo Lobo, Neil F. Sutanto, Inge Malar J Research BACKGROUND: A goal of malaria epidemiological interventions is the detection and treatment of parasite reservoirs in endemic areas—an activity that is expected to reduce local transmission. Since the gametocyte is the only transmissible stage from human host to mosquito vector, this study evaluated the pre and post presence of gametocytes during a mass screening and treatment (MST) intervention conducted during 2013 in East Nusa Tenggara, Indonesia. METHODS: RT-qPCR targeting pfs25 and pvs25 transcripts—gametocyte molecular markers for Plasmodium falciparum and Plasmodium vivax, respectively, was performed to detect and quantify gametocytes in blood samples of P. falciparum and P. vivax-infected subjects over the course of the MST study. The presence of both asexual and sexual parasites in microscopic and submicroscopic infections was compared from the start and end of the MST, using proportion tests as well as parametric and non-parametric tests. RESULTS: Parasite prevalence remained unchanged for P. falciparum (6% = 52/811 versus 7% = 50/740, p = 0.838), and decreased slightly for P. vivax (24% = 192/811 versus 19% = 142/740, p = 0.035) between the MST baseline and endpoint. No significant difference was observed in gametocyte prevalence for either P. falciparum (2% = 19/803 versus 3% = 23/729, p = 0.353, OR = 1.34, 95%CI = 0.69–2.63), or P. vivax (7% = 49/744 versus 5% = 39/704, p = 0.442, OR = 0.83, 95%CI = 0.52–1.31). Even though there was an insignificant difference between the two time points, the majority of parasite positive subjects at the endpoint had been negative at baseline (P. falciparum: 66% = 29/44, P. vivax: 60% = 80/134). This was similarly demonstrated for the transmissible stage—where the majority of gametocyte positive subjects at the endpoint were negative at baseline (P. falciparum: 95% = 20/21, P. vivax: 94% = 30/32). These results were independent of treatment provided during MST activities. No difference was demonstrated in parasite and gametocyte density between both time points either in P. falciparum or P. vivax. CONCLUSION: In this study area, similar prevalence rates of P. falciparum and P. vivax parasites and gametocytes before and after MST, although in different individuals, points to a negligible impact on the parasite reservoir. Treatment administration based on parasite positivity as implemented in the MST should be reevaluated for the elimination strategy in the community. Trial registration Clinical trials registration NCT01878357. Registered 14 June 2013, https://www.clinicaltrials.gov/ct2/show/NCT01878357. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-021-03709-y. BioMed Central 2021-04-09 /pmc/articles/PMC8034167/ /pubmed/33836772 http://dx.doi.org/10.1186/s12936-021-03709-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kosasih, Ayleen
Koepfli, Cristian
Dahlan, M. Sopiyudin
Hawley, William A.
Baird, J. Kevin
Mueller, Ivo
Lobo, Neil F.
Sutanto, Inge
Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study
title Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study
title_full Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study
title_fullStr Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study
title_full_unstemmed Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study
title_short Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study
title_sort gametocyte carriage of plasmodium falciparum (pfs25) and plasmodium vivax (pvs25) during mass screening and treatment in west timor, indonesia: a longitudinal prospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034167/
https://www.ncbi.nlm.nih.gov/pubmed/33836772
http://dx.doi.org/10.1186/s12936-021-03709-y
work_keys_str_mv AT kosasihayleen gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy
AT koepflicristian gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy
AT dahlanmsopiyudin gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy
AT hawleywilliama gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy
AT bairdjkevin gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy
AT muellerivo gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy
AT loboneilf gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy
AT sutantoinge gametocytecarriageofplasmodiumfalciparumpfs25andplasmodiumvivaxpvs25duringmassscreeningandtreatmentinwesttimorindonesiaalongitudinalprospectivestudy